Amsterdam-Duivendrecht, The Netherlands, October 9, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders, today announces the launch of an undocumented private… Continue reading Kiadis Pharma launches a private placement of approximately 2.25 million new shares
Author: Willem van Lawick
Kiadis Pharma appoints Dr. Andrew Sandler as Chief Medical Officer
Amsterdam-Duivendrecht, The Netherlands, September 29, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders, today announces the appointment of Dr. Andrew Sandler… Continue reading Kiadis Pharma appoints Dr. Andrew Sandler as Chief Medical Officer
Kiadis Pharma provides update on the Marketing Authorization Application process for ATIR101™ in Europe
Amsterdam-Duivendrecht, The Netherlands, September 27, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders, today announces that the Company has received and… Continue reading Kiadis Pharma provides update on the Marketing Authorization Application process for ATIR101™ in Europe
Kiadis Pharma receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation for ATIR101™
Amsterdam-Duivendrecht, The Netherlands, September 20, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders, today announces that the US Food and Drug… Continue reading Kiadis Pharma receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation for ATIR101™
Kiadis Pharma obtains up to €15 million debt financing from Kreos Capital
Amsterdam-Duivendrecht, The Netherlands, August 17, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders, today announces that it has obtained a debt… Continue reading Kiadis Pharma obtains up to €15 million debt financing from Kreos Capital
